Xeris Biopharma Holdings, Inc. (FRA:2B30)
6.38
-0.04 (-0.70%)
At close: Jan 23, 2026
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $74.38M USD in the quarter ending September 30, 2025, with 37.06% growth. This brings the company's revenue in the last twelve months to $266.14M, up 42.05% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$266.14M
Revenue Growth
+42.05%
P/S Ratio
4.53
Revenue / Employee
$675.47K
Employees
394
Market Cap
1.03B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |